Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 14/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 14/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 14/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | QDPR | P09417 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3527556 | 0.83 | TLR7 (0.47) | TLR9TLR8TLR7SOS1OPRM1 | |
| SCHEMBL2651932 | 0.82 | QDPR (0.60) | SOS1HRH3QDPR | |
| SCHEMBL14320745 | 0.81 | TLR8 (0.41) | TLR9TLR8TLR7SOS1OPRM1 | |
| SCHEMBL4615095 | 0.80 | NPC1 (0.45) | HRH3QDPR | |
| SCHEMBL3530693 | 0.80 | TLR9 (0.48) | TLR9TLR8TLR7 | |
| SCHEMBL520443 | 0.78 | QDPR (0.53) | TLR9TLR8TLR7QDPR | |
| SCHEMBL1570024 | 0.77 | TLR9 (0.43) | TLR9TLR8TLR7OPRM1OPRK1 | |
| SCHEMBL16994796 | 0.76 | TLR9 (0.51) | TLR9TLR8TLR7 | |
| SCHEMBL14321103 | 0.76 | ALDH1A1 (0.50) | TLR9TLR8TLR7 | |
| SCHEMBL30376009 | 0.75 | GPR119 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642270-B2 | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-05 | — | — | US | disclosed |
| US-20070060577-A1 | 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060577-A1 | 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | FLT3, FES, FGR | TLR9 2412/4885TLR8 1749/4885TLR7 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.